ATE314858T1 - Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen - Google Patents

Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen

Info

Publication number
ATE314858T1
ATE314858T1 AT99915251T AT99915251T ATE314858T1 AT E314858 T1 ATE314858 T1 AT E314858T1 AT 99915251 T AT99915251 T AT 99915251T AT 99915251 T AT99915251 T AT 99915251T AT E314858 T1 ATE314858 T1 AT E314858T1
Authority
AT
Austria
Prior art keywords
compositions
bacillus coagulans
systems
experience
reducing cholesterol
Prior art date
Application number
AT99915251T
Other languages
English (en)
Inventor
Sean Farmer
Andrew R Lefkowitz
Original Assignee
Ganeden Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ganeden Biotech Inc filed Critical Ganeden Biotech Inc
Application granted granted Critical
Publication of ATE314858T1 publication Critical patent/ATE314858T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A61K31/787—Polymers containing nitrogen containing heterocyclic rings having nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/742—Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
AT99915251T 1998-04-01 1999-04-01 Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen ATE314858T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8037898P 1998-04-01 1998-04-01

Publications (1)

Publication Number Publication Date
ATE314858T1 true ATE314858T1 (de) 2006-02-15

Family

ID=22157005

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99915251T ATE314858T1 (de) 1998-04-01 1999-04-01 Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen

Country Status (8)

Country Link
EP (1) EP1067945B1 (de)
JP (2) JP5108174B2 (de)
AT (1) ATE314858T1 (de)
AU (1) AU3380899A (de)
CA (1) CA2326874C (de)
DE (1) DE69929321T2 (de)
ES (1) ES2258841T3 (de)
WO (1) WO1999049877A2 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
US7998470B2 (en) 1999-04-30 2011-08-16 Kibow Biotech, Inc. Compositions and methods improving renal function
US6849256B1 (en) 1999-11-08 2005-02-01 Ganeden Biotech Incorporated Inhibition of pathogens by probiotic bacteria
EP1229923A1 (de) * 1999-11-08 2002-08-14 Ganeden Biotech, Inc. Hemmung von pathogenen durch bacillus coagulans stämme
JP4580542B2 (ja) * 2000-05-17 2010-11-17 株式會社バイオニア 肥満又は糖尿病治療用微生物及びその微生物を含む医薬組成物
AUPR101600A0 (en) * 2000-10-25 2000-11-16 Atheromastat Pty Ltd Compositions and methods for diagnosis and treatment of cardiovascular disorders
IL156490A0 (en) * 2000-12-18 2004-01-04 Probiohealth Probiotic compounds derived from lactobacillus casei strain ke01
ITMI20011632A1 (it) * 2001-07-27 2003-01-27 Sanofi Synthelabo Composizione solida contenente spore di batteri non patogeni del genere bacillus
WO2003013559A1 (en) * 2001-08-10 2003-02-20 Hokkaido Technology Licensing Office Co., Ltd. Bile acid absorbent/adsorbent
US20030124104A1 (en) * 2001-11-05 2003-07-03 Sean Farmer Probiotic compositions
MXPA04008177A (es) * 2002-02-21 2005-06-08 Nestle Sa Composicion oralmente administrable, para la fotoproteccion de la piel.
US9980988B2 (en) 2002-03-13 2018-05-29 Kibow Biotech, Inc. Compositions and methods for augmenting kidney function
CN100402042C (zh) * 2002-03-13 2008-07-16 基博生物技术公司 增强肾功能的组合物及方法
US20050074442A1 (en) 2002-03-13 2005-04-07 Natarajan Ranganathan Compositions and methods for augmenting kidney function
US9655932B2 (en) 2002-03-13 2017-05-23 Kibow Biotech, Inc. Composition and method for preventing or treating gout or hyperuricemia
US11103542B2 (en) 2002-03-13 2021-08-31 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
ES2315510T3 (es) * 2002-06-13 2009-04-01 Novartis Ag Sales de calcio de estatinas derivadas del indol.
JP2004244365A (ja) * 2003-02-13 2004-09-02 Hokkaido Technology Licence Office Co Ltd 二次胆汁酸の生成抑制剤
US7854927B2 (en) * 2004-05-11 2010-12-21 Ganeden Biotech, Inc. Methods and compositions for the dietary management of autoimmune disorders
AU2005257033B2 (en) 2004-06-23 2011-05-12 L'oreal Method and compositions useful for preventing and/or treating sensitive and/or dry skin
GB0424552D0 (en) * 2004-11-05 2004-12-08 Cambridge Theranostics Ltd Methods and means
EP1885207B1 (de) * 2005-05-18 2011-07-06 DSM IP Assets B.V. Zusammensetzung für die enterale verabreichung von mikroorganismen
KR101454228B1 (ko) 2006-08-21 2014-10-23 칼피스가부시키가이샤 지질-대사 개선제
EE200600034A (et) * 2006-10-11 2008-06-16 Tartu Ülikool Meetod sporogeensete fermenteeritavate termofiilsete mikroorganismi tvede endospooride saamiseks ja saadud endospooride kasutamine fermentatsiooni inokuleerimiseks
FR2920304B1 (fr) 2007-09-04 2010-06-25 Oreal Utilisation cosmetique de lysat bifidobacterium species pour le traitement de la secheresse.
FR2920305B1 (fr) 2007-09-04 2010-07-30 Oreal Utilisation d'un lysat de bifidobacterium species pour le traitement de peaux sensibles.
JP2009297011A (ja) * 2008-06-17 2009-12-24 Food Business Supply:Kk 菊芋こんにゃく
GB0900350D0 (en) * 2009-01-09 2009-02-11 Cambridge Entpr Ltd Formulations of viable bacteria for oral delivery
FR2942719B1 (fr) 2009-03-04 2011-08-19 Oreal Utilisation de microorganismes probiotiques pour limiter les irritations cutanees
EP2424550B1 (de) 2009-04-29 2017-06-07 Ganeden Biotech, Inc. Bakterienzellmembran formulierung
WO2011111783A1 (ja) * 2010-03-12 2011-09-15 カルピス株式会社 大腸におけるビフィズス菌の増加及び減少抑制剤
BR112013004194A2 (pt) * 2010-08-25 2016-05-10 Tate & Lyle Ingredients produto simbiótico
IT1403661B1 (it) 2011-01-28 2013-10-31 Probiotical Spa Composizione effervescente in forma solida per uso in applicazioni vaginali per il trattamento di infezioni vaginali.
US11235008B2 (en) 2011-03-31 2022-02-01 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
JP5892580B2 (ja) * 2011-04-14 2016-03-23 国立大学法人 琉球大学 新規乳酸菌及びｌ−乳酸の製造方法及び乳酸菌を含む食品および薬品
ITMI20110792A1 (it) * 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri appartenenti al genere bifidobacterium per uso nel trattamento della ipercolesterolemia.
ITMI20110791A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri in grado di metabolizzare gli ossalati.
ITMI20110793A1 (it) 2011-05-09 2012-11-10 Probiotical Spa Ceppi di batteri probiotici e composizione sinbiotica contenente gli stessi destinata alla alimentazione dei neonati.
ITRM20110477A1 (it) 2011-09-09 2013-03-10 Giovanni Mogna Composizione comprendente n-acetilcisteina e/o lisozima microincapsulato gastroprotetto in associazione con batteri probiotici in grado di ripristinare l'effetto barriera proprio dello stomaco che viene perso durante il trattamento farmacologico dell
ITMI20111718A1 (it) 2011-09-23 2013-03-24 Probiotical Spa Un materiale impermeabile alla umidita e allo ossigeno per confezionare prodotti dietetici, cosmetici e specialita medicinali.
US8268305B1 (en) 2011-09-23 2012-09-18 Bio-Cat, Inc. Method and compositions to reduce serum levels of triacylglycerides in human beings using a fungal lipase
JP5921894B2 (ja) * 2012-01-20 2016-05-24 アサヒカルピスウェルネス株式会社 腸内酪酸産生菌増加剤
ITMI20130793A1 (it) 2013-05-14 2014-11-15 Probiotical Spa Composizione comprendente batteri lattici per uso nel trattamento preventivo e/o curativo delle cistiti ricorrenti.
GB201319525D0 (en) * 2013-11-05 2013-12-18 Optibiotix Health Ltd Composition
CA2955111A1 (en) * 2014-08-29 2016-03-03 Muhammed Majeed Process for enhancing the viable counts of lactic acid bacteria and useful compositions thereof
ITUA20162013A1 (it) 2016-03-24 2017-09-24 Probiotical Spa Composizione a base di batteri lattici per il trattamento contemporaneo di infezioni vaginali di origine micotica e batterica.
JP2017190298A (ja) * 2016-04-13 2017-10-19 博 小田 体内で水素を産生する組成物、及びサプリメント
GB201611782D0 (en) * 2016-07-06 2016-08-17 Optibiotix Ltd Composition
WO2018125735A1 (en) 2016-12-29 2018-07-05 Kibow Biotech, Inc. Composition and method for maintaining healthy kidney function
WO2018226271A1 (en) * 2017-06-09 2018-12-13 Muhammed Majeed Hypolipidemic effects of bacillus coagulans
CN110831609A (zh) * 2017-06-30 2020-02-21 N·V·努特里奇亚 用于预防代谢紊乱的合生素组合物
EP4159224A1 (de) 2017-06-30 2023-04-05 N.V. Nutricia Synbiotische zusammensetzung zur vorbeugung von chronischer entzündung
CN110317757B (zh) * 2019-07-16 2020-09-25 自然资源部第三海洋研究所 一株具降胆固醇及富硒作用的植物乳杆菌hj-s2及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4110477A (en) * 1977-05-13 1978-08-29 Kabushiki Kaisha Naruse Fermentation Laboratory Method for producing natto containing lactic acid bacteria
JPS6261572A (ja) * 1985-09-12 1987-03-18 Nippon Oil & Fats Co Ltd スプレツドおよびその製法
JPH0352131Y2 (de) * 1986-01-20 1991-11-11
JP2806522B2 (ja) * 1987-09-04 1998-09-30 日本食品化工株式会社 分岐フラクトオリゴ糖の製造方法
JPH0678367B2 (ja) * 1990-05-15 1994-10-05 呉羽化学工業株式会社 食物繊維、その製造法及びその食物繊維を含有する生理活性剤
JPH09194384A (ja) * 1996-01-19 1997-07-29 Snow Brand Milk Prod Co Ltd ミネラル吸収促進剤
JPH10306028A (ja) * 1997-05-06 1998-11-17 Koji Haraguchi 脂質消化吸収阻害整腸剤

Also Published As

Publication number Publication date
EP1067945A2 (de) 2001-01-17
AU3380899A (en) 1999-10-18
WO1999049877A3 (en) 1999-12-16
WO1999049877A2 (en) 1999-10-07
DE69929321D1 (de) 2006-03-30
CA2326874C (en) 2010-05-25
JP2010095532A (ja) 2010-04-30
JP2002509891A (ja) 2002-04-02
CA2326874A1 (en) 1999-10-07
ES2258841T3 (es) 2006-09-01
JP5108174B2 (ja) 2012-12-26
EP1067945B1 (de) 2006-01-04
DE69929321T2 (de) 2006-09-14

Similar Documents

Publication Publication Date Title
DE69929321D1 (de) Erfahren zür verringerung von cholesterin mit bacillus coagulans sporen, systeme un zusammensetzungen
IL137093A0 (en) Methods of inactivating bacteria including bacterial spores
ATE163042T1 (de) Lactobazillusstämme menschlichen ursprungs, ihre zusammensetzung und deren verwendung
TR200103216T2 (tr) Pirimidinon bileşimleri
DE69635419D1 (de) Alkalophile und thermophile mikroorganismen und damit erhaltene enzymen
NZ502610A (en) Use of lactobacillus for reduction of the fibrinogen level in blood
DE69924141D1 (de) Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
IL140710A0 (en) Pulmonary delivery of active agents
AU1909200A (en) Pyridin-4-yl or pyrimidin-4-yl substituted pyrazines
CA2366084A1 (fr) Milieu chromogene de detection de staphylococcus aureus
WO1997040072A3 (en) Adam proteins and uses thereof
MY131300A (en) Antibacterial agents
AU5892399A (en) 1, 2, 4-triazole-3-thione compounds
AU7918500A (en) Substituted diazepanes
AU3115595A (en) Pyridylthio compounds for controlling helicobacter bacteria
AU4414400A (en) Lactic acid bacteria with anxiolytic properties and uses thereof
WO2000003724A1 (en) Preparations for immunotherapy for cancer having bacterial somatic constituent as the active ingredient
CA2293808A1 (en) Methods and compositions for diagnosis and treatment of iron overload diseases and iron deficiency diseases
IL128500A (en) SUBSTITUTED 1,2,3,4-TETRAHYDRO-2-DIBENZOFURANAMINES AND 2-AMINOCYCLOHEPTA[b] BENZOFURANS AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
DE59510131D1 (de) Imidazopyridin-azolidinone
NZ505637A (en) E-2-[4-(4-chloro-1,2-diphenyl-but-1-enyl)phenoxy]ethanol and pharmaceutical compositions useful in lowering serum cholesterol
GB9711389D0 (en) Bacterial pheromones and uses therefor
GB9513110D0 (en) Dairy system cleaning preparation and method
AU2356001A (en) Surface treatment agent for laminated fabric
DE59409983D1 (de) Pyridiniumsalze und ihre verwendung zur bekämpfung von helicobacter-bakterien

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1067945

Country of ref document: EP